Evaluation of serum level of furin enzyme activity, fatty acid binding protein-4 (FABP-4) and insulin resistance in patients with pre-diabetes and newly diagnosed type 2 diabetes mellitus
Abstract
Objectives: To study the levels of furin enzyme activity (FEA) and fatty acid binding protein-4 (FABP-4) in the serum as vital indicators in pre-diabetes patients, newly diagnosed type 2 diabetes mellitus (ND-T2DM) patients, and insulin resistance, and compare with that of healthy control group, as a predictor of risk factors.
Methodology: The current study included 180 adult participants; 50 newly diagnosed with T2DM (28 men and 22 women), 50 with pre-diabetes (27 men and 23 women), compared with 80 healthy volunteers as a control group (44 men and 36 women). We examined serum levels of FEA, FABP-4 levels and insulin hormone.
Results: The results in the current study showed that the average effectiveness of furin enzyme in newly diagnosed T2DM patients was very much lower than it was in the control group± 0.53) 0.06 pg/mL) and in the pre-diabetes group it was significantly less than the control group (0.85 ± 0.26 pg/mL). The levels of effectiveness of furin enzyme were significantly high in the control group (1.70 ± 0.66) (P < 0.0001).
Conclusions: The effectiveness of the furin enzyme in newly diagnosed type.2 diabetes mellitus patients and pre-diabetes has not been previously studied. We conclude that measurements of the furin enzyme activity and fatty acid binding protein-4 in serum, are indicators of risk factors for type.2 diabetes mellitus patients.
Abbreviations: ADA - American Diabetes Association; CAD - coronary artery disease; DM - diabetes mellitus; FEA - furin enzyme activity; FABP-4 - fatty acid binding protein-4; FBG - Fasting blood glucose; T2DM - type 2 diabetes mellitus; ND-T2DM - Newly diagnosed T2DM; IGT - impaired glucose tolerance;
Keywords: Diabetes mellitus; Furin enzyme activity, FABP-4, Insulin resistance, Prediabetics
Citation: Obaid ZS, Al-Wasiti EAR, Deli FA. Evaluation of serum level of furin enzyme activity, fatty acid binding protein-4 (FABP-4) and insulin resistance in patients with pre-diabetes and newly diagnosed type 2 diabetes mellitus. Anaesth. pain intensive care 2024;28(4):712−720; DOI: 10.35975/apic.v28i4.2514
Received: December 06, 2023; Reviewed: March 07, 2024; Accepted: March 14, 2024